Stock Ticker

  • Loading stock data...

PhaseRx Inc (NASDAQ:PZRX) Updates On Orphan Drug Designation For PRX-ASL

PhaseRx Inc (NASDAQ:PZRX) reported that the European Medicines Agency’s COMP has given a positive view recommending orphan medicinal product status for PRX-ASL, for the cure of argininosuccinate lyase deficiency, the company’s second drug candidate to cure a urea cycle disorder.

The details

ASLD can be stated as a rare liver disorder, which is a result of an inherited single-gene deficiency leading in hyperammonemia. It can even result in irreversible neurological impairment, death and coma. PRX-ASL is an i-ERT intended to replace the defective or missing enzyme in people with ASLD, thereby correcting the ailment. PRX-ASL has demonstrated therapeutic prospect in a preclinical model of ASLD, counting decline in the compounds levels whose elevation are the mark of ASLD such as argininosuccinic acid, blood ammonia and plasma citrulline.

Robert W. Overell, Ph.D., the CEO and President of PhaseRx, expressed that this positive stance recommending orphan drug status for PRX-ASL in the EU is a notable step in the advancement of this candidate, and follows a same decision by the U.S. FDA in September. They are delighted that the respective committee has affirmed their belief in the requirement for a new therapeutic for this disease. Applications for orphan designation are primarily reviewed by the COMP. Constructive opinions are then sent to the European Commission, which is accountable for formally allowing the orphan designation.

This status in the European Union is provided to products that are planned for the treatment, diagnosis or prevention of a disease that is chronically debilitating or life-threatening; where prevalence of the disease in the European Union is less than five in 10,000; and where the offering exhibits a notable benefit over current treatments. PhaseRx is a biopharmaceutical firm committed to advancing mRNA offerings for the treatment of kids with hereditary enzyme deficiencies in the liver utilizing intracellular enzyme replacement therapy.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email ([email protected]) or his Google+ page (

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts